Home-based pulmonary rehabilitation for interstitial lung disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial evaluates a 6-week home-based pulmonary rehabilitation program delivered with telemonitoring versus standard care in adults with fibrotic interstitial lung disease. Participants will engage in guided exercises, education, and behavior support, with remote monitoring to enhance adherence. The goal is to determine effects on health-related quality of life and exercise capacity in a resource-limited setting. This interventional study is conducted at a single center in Chandigarh, India, with adults aged 18 to 75 who are on stable immunosuppressive or antifibrotic therapy. Safety and feasibility will also be considered, given the home-based delivery model.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age between 18 and 75 years
2. Diagnosis of an ILD by clinician using standard guidelines
3. Having breathlessness graded 1 to 3 on the modified Research Council (mMRC) scale
4. On stable therapy with immunosuppressants or antifibrotics for 3 or more months

Exclusion Criteria:

1. Pregnant or lactating women
2. Unwilling to participate in the study
3. Not able to walk or perform upper and lower limb movements
4. Requiring supplemental oxygen

Where it's running

• Post graduate Institute of Medical Education and Research
  Chandigarh, Chandigarh, India Recruiting

Study contacts

• Study coordinator: Sahajal Dhooria, MD, DM
• Email: sahajal@gmail.com
• Phone: +91 172 2756827

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Photon-counting CT vs standard HRCT to help diagnose IPF and other ILDs

  This study tests whether photon-counting CT can improve identifying IPF and other ILDs compared with standard HRCT for patients discussed in multidisciplinary teams.

  Recruiting Istituto Clinico Humanitas · Rozzano, Italy · NCT07790614

• Nerandomilast for fibrosing interstitial lung disease at risk of progression

  This trial tests whether nerandomilast can help adults with fibrosing interstitial lung disease who are at risk of their disease getting worse.

  Recruiting at 7 sites Phase 3 Boehringer Ingelheim · Birmingham, Alabama and 161 other locations · NCT07540988

• Nerandomilast to slow lung changes in people with a family history of pulmonary fibrosis

  This trial tests whether taking nerandomilast can slow early lung scarring in people aged 40 and older who have a first-degree relative with pulmonary fibrosis and CT evidence of interstitial lung abnormalities.

  Recruiting at 52 sites Phase 3 Boehringer Ingelheim · Los Angeles, California and 54 other locations · NCT07201922

• Ultra‑high‑resolution CT to look for lung and heart damage in progressive interstitial lung disease

  This project will use advanced multidimensional CT scans to see if one noninvasive test can measure both lung fibrosis and early heart involvement in adults with progressive or long‑standing interstitial lung disease.

  Recruiting IRCCS San Raffaele · Milan · NCT06537934

• Evaluating a new CAR T cell therapy for systemic sclerosis

  This study is testing a new CAR T cell therapy to see if it can help people with systemic sclerosis feel better and manage their symptoms.

  Recruiting at 10 sites Phase 2/3 Cabaletta Bio · New Haven, Connecticut and 9 other locations · NCT06328777

• Understanding functional status in people with interstitial lung disease

  This study is trying to understand how interstitial lung disease affects people's daily activities and overall health, while also looking at what factors might make it worse.

  Recruiting Aveiro University · Aveiro · NCT06317831

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.